Laurion Capital Management LP Increases Position in Protagonist Therapeutics Inc (PTGX)

Laurion Capital Management LP lifted its position in shares of Protagonist Therapeutics Inc (NASDAQ:PTGX) by 400.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 85,641 shares of the company’s stock after buying an additional 68,541 shares during the period. Laurion Capital Management LP’s holdings in Protagonist Therapeutics were worth $1,077,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. D. E. Shaw & Co. Inc. increased its stake in Protagonist Therapeutics by 75.5% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 19,645 shares of the company’s stock worth $132,000 after purchasing an additional 8,450 shares during the period. Bank of Montreal Can grew its position in shares of Protagonist Therapeutics by 1,675.5% in the 1st quarter. Bank of Montreal Can now owns 11,026 shares of the company’s stock worth $139,000 after buying an additional 10,405 shares during the last quarter. Bank of America Corp DE grew its position in shares of Protagonist Therapeutics by 94.3% in the 4th quarter. Bank of America Corp DE now owns 26,419 shares of the company’s stock worth $178,000 after buying an additional 12,819 shares during the last quarter. Northern Trust Corp grew its position in shares of Protagonist Therapeutics by 17.2% in the 4th quarter. Northern Trust Corp now owns 34,624 shares of the company’s stock worth $234,000 after buying an additional 5,084 shares during the last quarter. Finally, Tibra Equities Europe Ltd bought a new stake in shares of Protagonist Therapeutics in the 1st quarter worth approximately $410,000. 59.89% of the stock is currently owned by institutional investors.

Shares of PTGX stock opened at $10.92 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.02 and a current ratio of 5.02. Protagonist Therapeutics Inc has a fifty-two week low of $5.49 and a fifty-two week high of $14.36. The company has a market capitalization of $256.89 million, a PE ratio of -6.28 and a beta of 1.96.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.58) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.01. Protagonist Therapeutics had a negative return on equity of 40.78% and a negative net margin of 209.02%. The company had revenue of $1.56 million for the quarter, compared to analyst estimates of $2.50 million. Research analysts forecast that Protagonist Therapeutics Inc will post -2.36 earnings per share for the current year.

A number of equities research analysts have recently weighed in on PTGX shares. ValuEngine upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, March 25th. Zacks Investment Research upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $8.25 price objective on the stock in a research report on Thursday, February 21st. Stifel Nicolaus upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $11.00 to $17.00 in a research report on Wednesday, May 8th. BidaskClub lowered Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 13th. Finally, BMO Capital Markets started coverage on Protagonist Therapeutics in a research report on Friday, February 22nd. They issued an “outperform” rating and a $17.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $16.33.

ILLEGAL ACTIVITY WARNING: This article was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.baseballdailydigest.com/news/2019/05/24/laurion-capital-management-lp-increases-position-in-protagonist-therapeutics-inc-ptgx.html.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Featured Story: Why do companies issue convertible shares?

Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics Inc (NASDAQ:PTGX).

Institutional Ownership by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.